Welcome to our dedicated page for Reunion Neuroscience news (Ticker: REUN), a resource for investors and traders seeking the latest updates and insights on Reunion Neuroscience stock.
Reunion Neuroscience Inc. (REUN) pioneers next-generation mental health treatments through its neuroscience research and therapeutic innovations. This dedicated news hub provides investors and healthcare professionals with essential updates on clinical advancements, corporate developments, and strategic initiatives.
Access verified information about the company's RE200 series of receptor-selective compounds and Rizikon cybersecurity analytics. Our curated news collection covers FDA milestones, research partnerships, and intellectual property updates, offering a comprehensive view of REUN's progress in neuropharmaceutical development.
Key updates include clinical trial phases, regulatory filings, university collaborations, and technology deployments. All content is sourced from official channels to ensure compliance with financial disclosure standards.
Bookmark this page for streamlined access to Reunion Neuroscience's latest developments. For direct updates, subscribe to company alerts through their investor portal or follow their official social channels.
Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) is hosting a corporate presentation at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 26, 2023. The presentation will detail the company's innovative therapeutic solutions for mental health conditions, focusing on its lead asset, RE104, a novel compound aimed at treating postpartum depression. RE104 is protected by U.S. Patent No. 11,292,765, which extends its protection until June 30, 2041. The conference is scheduled for April 25-26, 2023, at the Metro Toronto Convention Centre, with one-on-one meetings for institutional investors also available. Information on accessing the presentation webcast can be found on Reunion's website.
Reunion Neuroscience Inc. (NASDAQ: REUN) announced it received a notice from Nasdaq on April 19, 2023, indicating that its common shares did not meet the minimum bid price requirement of $1.00 per share over a 30-day period, ending April 18, 2023. The company has a compliance period of 180 days, until October 16, 2023, to regain compliance by maintaining a minimum bid price of at least $1.00 for ten consecutive business days. If compliance is not achieved, Reunion may be eligible for an additional 180-day period, but risks delisting if unable to cure the deficiency. No immediate impact on the company's business operations or share listing has been reported. Reunion is focused on developing innovative treatments for mental health conditions, including its lead asset, RE104, aimed at postpartum depression.
FAQ
What is the market cap of Reunion Neuroscience (REUN)?
